Following the changes to remove technical engagement as standard from appraisal timelines, the timelines for the appraisal of Cedazuridine–decitabine for untreated acute myeloid leukaemia unsuitable for intensive chemotherapy have been revised. It is anticipated that the appraisal will begin in early-June 2023 when we will write to you about how you can get involved.